TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21708042

Group type: EXPERIMENTAL
Intervention: HVLA‐SM (High-Velocity Low-Amplitude Spinal Manipulation)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: LVVA‐SM (Low-Velocity Variable-Amplitude Spinal Manipulation)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: HVLA‐SM
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: LVVA‐SM
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: HVLA‐SM and LVVA‐SM
Number of subjects: 219
Study: 19699875

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) measurement
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control (nonobese patients)
Number of subjects: 452
Study: 16432472

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Single-vision lenses (SVLs)
Number of subjects: 469
Study: 15540852

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 0
Study: 11495219

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 1733
Study: 1284152

Group type: EXPERIMENTAL
Intervention: Gallopamil (0.4 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6331302

Group type: EXPERIMENTAL
Intervention: Cefotiam
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 39
Study: 31107046

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) for PTSD
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study: 29265934

Group type: EXPERIMENTAL
Intervention: Serelaxin treatment
Number of subjects: 63
Study: 26654280

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24572769

Group type: EXPERIMENTAL
Intervention: CABG and irrigated radiofrequency pulmonary vein isolation (CABG+PVI, n = 31)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CABG and an irrigated radiofrequency modified mini‐maze procedure (CABG+MM, n = 30)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Isolated CABG (CABG alone, n = 34)
Number of subjects: 95
Study: 21856721

Group type: EXPERIMENTAL
Intervention: Eccentric training of patellar tendon and static stretching exercises of quadriceps and hamstrings (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Eccentric training of patellar tendon (Group B)
Number of subjects: 43
Study: 20604700

Group type: EXPERIMENTAL
Intervention: Keep Active Minnesota (KAM) intervention
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1049
Study: 18300224

Group type: EXPERIMENTAL
Intervention: ADRO MAP
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard MAP
Number of subjects: 15
Study: 15942151

Group type: EXPERIMENTAL
Intervention: Local estrogen cream
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chlindamycine phosphate cream (placebo)
Number of subjects: 45
Study: 12598351

Group type: COMPARATOR
Intervention: Doxorubicin (DOX) 60 mg/m2 alone
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 60 mg/m2 and Cisplatin (CDDP) 50 mg/m2 every 4 weeks
Number of subjects: 177
Study: 9890307

Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.025 to 0.2 mg/h nitroglycerin patch
Number of subjects: 13
Study: 8635139

Group type: EXPERIMENTAL
Intervention: Patients without tumor necrosis
Number of subjects: 299

Group type: COMPARATOR
Intervention: Patients with tumor necrosis
Number of subjects: 299
Study: 2017970

Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status score < 8
Number of subjects: 849
Study: 2981827

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg injections)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meperidine (50 mg injections)
Number of subjects: 20
Study: 29902939

Group type: EXPERIMENTAL
Intervention: Twice-daily early therapeutic mobility (ETM)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Moderate-intensity (out-of-bed) ETM
Number of subjects: 54

Group type: COMPARATOR
Intervention: Once-daily early therapeutic mobility (ETM)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low-intensity (in-bed) ETM
Number of subjects: 54
Study: 27814865

Group type: COMPARATOR
Intervention: Hip muscle strengthening exercises (E)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hip muscle strengthening exercises with myofascial techniques (EM)
Number of subjects: 18
Study: 25475143

Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Open Flap Debridement (OFD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (OFD)
Number of subjects: 10
Study: 23759286

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive-behavioral therapy including a virtual reality protocol (ECT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard cognitive behavior therapy (CBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Inpatient multimodal treatment (IP)
Number of subjects: 90
Study: 21235604

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Infliximab (IFX)
Number of subjects: 51
Study: 18504392

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: GH untreated
Number of subjects: 40
Study: 17179478

Group type: EXPERIMENTAL
Intervention: Dietary intervention (reduced fat intake)
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 2437
Study: 15573624

Group type: EXPERIMENTAL
Intervention: Donut round
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional lecture
Number of subjects: 106
Study: 11066464

Group type: EXPERIMENTAL
Intervention: Experimental Program (antenatal smoking cessation intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider compliance assessment via audiotapes and checklists
Number of subjects: 0
Study: 8733032

Group type: EXPERIMENTAL
Intervention: High salt intake (habitual +50/100 mmol/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Habitual salt intake
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low salt intake (habitual -50/100 mmol/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Increase in salt intake (100 mmol/day)
Number of subjects: 14
Study: 1613273

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 137
Study: 6381101

Group type: EXPERIMENTAL
Intervention: Hydrotubation with lactated Ringer's solution
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Hydrotubation with hydrocortisone
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (no hydrotubation)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Moderate and severe disease
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Previous pregnancies
Number of subjects: 206
Study: 31845901

Group type: EXPERIMENTAL
Intervention: Voice messages (n=43)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Text messages (n=40)
Number of subjects: 54
Study: 29916859

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 352

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 352

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 352
Study: 26673352

Group type: EXPERIMENTAL
Intervention: Vinflunine plus Gemcitabine (VG)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vinflunine plus Carboplatin (VC)
Number of subjects: 69
Study: 25037139

Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg twice a day and cobimetinib 60 mg once a day 21/7
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg twice a day and cobimetinib 80 mg once a day 14/14
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg twice a day and cobimetinib 60 mg 28/0
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: vemurafenib and cobimetinib (various dosing regimens)
Number of subjects: 129
Study: 21985892

Group type: EXPERIMENTAL
Intervention: Interactive Web-based module on injury prevention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Noninteractive Web-based module on injury prevention (Control)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both modules (Interactive and Noninteractive)
Number of subjects: 57
Study: 20139340

Group type: EXPERIMENTAL
Intervention: Calcium-phosphate cement (Ca-P) used for indirect pulp-capping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (without Ca-P base)
Number of subjects: 0
Study: 17392043

Group type: EXPERIMENTAL
Intervention: Mild induced hypothermia (reduction of body temperature by about 3 degrees C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild induced hypothermia
Number of subjects: 0
Study: 17012883

Group type: EXPERIMENTAL
Intervention: Fluarix (TIV)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 956
Study: 12150241

Group type: EXPERIMENTAL
Intervention: Motivated correction explanation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive strategies and motivational priorities
Number of subjects: 0
Study: 10214832

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (2.5 mg, 5 mg, 10 mg, 15 mg) combined with 2 mg of micronized 17beta-estradiol
Number of subjects: 194
Study: 7605019

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at concentrations of 1, 3, 10, 30, and 100 ppm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 6
Study: 2213103

Group type: EXPERIMENTAL
Intervention: VAC plus ADR (radiotherapy to primary lesion plus cyclophosphamide, vincristine, dactinomycin, and Adriamycin)
Number of subjects: 342

Group type: COMPARATOR
Intervention: VAC alone (radiotherapy to primary lesion plus cyclophosphamide, vincristine, dactinomycin)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: VAC plus BPR (radiotherapy to primary lesion plus cyclophosphamide, vincristine, dactinomycin, plus bilateral pulmonary radiotherapy)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: VAC plus ADR
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: VAC plus BPR
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 342

Group type: COMPARATOR
Intervention: Pelvic disease
Number of subjects: 342

Group type: COMPARATOR
Intervention: Nonpelvic disease
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Overall incidence of metastatic disease
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Overall incidence of local recurrence
Number of subjects: 342
Study: 87965

Group type: EXPERIMENTAL
Intervention: T3 20 micrograms four times daily from surgery through the twelfth postoperative month
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: T3 20 micrograms four times daily
Number of subjects: 36
Study: 30939507

Group type: EXPERIMENTAL
Intervention: TXA (15 mg/kg IV before incision and a second identical dose 3 hours after the initial dose)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (no TXA)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: TXA
Number of subjects: 93
Study: 28357822

Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump under normobaric conditions (101.3 kPa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump under 203 kPa hyperbaric condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump under 243 kPa hyperbaric condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump under 284 kPa hyperbaric condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump using ceftazidime 6 g under 203 kPa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump using ucloxacillin 8 g
Number of subjects: 0
Study: 26194874

Group type: EXPERIMENTAL
Intervention: Total Shoulder Arthroplasty (TSA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Arthroplasty (RSA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 24
Study: 23401198

Group type: EXPERIMENTAL
Intervention: High-frequency supraorbital stimulation (400 Hz, 28 trains of nine stimuli)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study: 21480103

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1 g b.i.d., Furazolidone 200 mg b.i.d., Omeprazole 20 mg b.i.d., Bismuth subcitrate 240 mg b.i.d. for two weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Amoxicillin 1 g b.i.d., Furazolidone 200 mg b.i.d., Omeprazole 20 mg b.i.d. (without Bismuth)
Number of subjects: 70
Study: 19806293

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 72

Group type: COMPARATOR
Intervention: No regular exercise (Control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (Exercise and Control)
Number of subjects: 72
Study: 17146320

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (18 mug)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12663590

Group type: EXPERIMENTAL
Intervention: Rapid A1c availability
Number of subjects: 597

Group type: COMPARATOR
Intervention: Routine A1c availability
Number of subjects: 597
Study: 11001106

Group type: EXPERIMENTAL
Intervention: Jet injector (Injex)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Needle syringe
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Jet injector and Needle syringe)
Number of subjects: 40
Study: 9167112

Group type: EXPERIMENTAL
Intervention: Extended-release glipizide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (glipizide and placebo)
Number of subjects: 25
Study: 8467322

Group type: EXPERIMENTAL
Intervention: Low dose insulin infusion (5 mU/m2/min) during clamp A
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High dose insulin infusion (60 mU/m2/min) during clamp B
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard drug therapy (50 mg atenolol + 30 mg furosemide per day) prior to each clamp
Number of subjects: 6
Study: 2431015

Group type: EXPERIMENTAL
Intervention: Permethrin 5% dermal cream
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lindane 1% lotion
Number of subjects: 46
Study: 31219270

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) for 6 weeks
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 267
Study: 30344655

Group type: EXPERIMENTAL
Intervention: Two‐time lavage group
Number of subjects: 120
Study: 27120478

Group type: EXPERIMENTAL
Intervention: HOMA:IR measurement in women who developed puerperal infection
Number of subjects: 1180

Group type: COMPARATOR
Intervention: HOMA:IR measurement in women who did not develop puerperal infection
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Logistic regression controlling for confounders
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Predictive value of elevated HOMA:IR
Number of subjects: 1180
Study: 25550062

Group type: EXPERIMENTAL
Intervention: Quarterly self-care and nutrition-education program delivered by case managers (intervention group, n=789)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Standard care (control group, n=271)
Number of subjects: 1060
Study: 22844053

Group type: EXPERIMENTAL
Intervention: Fusion group (23 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-fusion group (24 patients)
Number of subjects: 50
Study: 20420270

Group type: EXPERIMENTAL
Intervention: Increased progesterone dosage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard progesterone dosage (Control)
Number of subjects: 0
Study: 18488134

Group type: EXPERIMENTAL
Intervention: Web-based administration of PFDI-20
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Web-based administration of PFIQ-7
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Preference for web-based format
Number of subjects: 52
Study: 15596631

Group type: EXPERIMENTAL
Intervention: Survey administered to participants regarding attitudes, beliefs, and practices about ACP
Number of subjects: 700
Study: 11703888

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gender-specific data analysis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NIH Revitalization Act
Number of subjects: 120
Study: 9164506

Group type: COMPARATOR
Intervention: Nissen fundoplication (360 degrees fundoplication)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Modified Hill operation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Modified Hill operation with intraoperative manometry (IOM)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Modified Hill operation without intraoperative manometry (IOM)
Number of subjects: 72
Study: 7970589

Group type: EXPERIMENTAL
Intervention: Miconazole lacquer
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo lacquer
Number of subjects: 36
Study: 3300171

Group type: EXPERIMENTAL
Intervention: Citalopram (30-60 mg daily for at least 3 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Amitriptyline (75-225 mg daily for at least 3 weeks)
Number of subjects: 43
Study: 31081342

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 6629
Study: 30166290

Group type: EXPERIMENTAL
Intervention: 6-month self-rehabilitation programme in addition to botulinum toxin injections (BTIs) and conventional physiotherapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Botulinum toxin injections (BTIs) alone and conventional physiotherapy
Number of subjects: 220
Study: 27050709

Group type: EXPERIMENTAL
Intervention: Self-suggested rest interval (RI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Fixed 2 min rest interval (RI)
Number of subjects: 27
Study: 26600066

Group type: EXPERIMENTAL
Intervention: White bread with EOC (two bottles)
Number of subjects: 10

Group type: COMPARATOR
Intervention: White bread
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: White bread with EOC
Number of subjects: 10
Study: 23089076

Group type: EXPERIMENTAL
Intervention: Open-label glycine at doses titrated to 0.8 g/kg/d for 8 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Double-blind glycine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Open-label glycine for another 12 weeks after the double-blind phase
Number of subjects: 18
Study: 20434046

Group type: EXPERIMENTAL
Intervention: Etidronate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18203079

Group type: EXPERIMENTAL
Intervention: T1225 0.5% eyedrops
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: T1225 1.0% eyedrops
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: T1225 1.5% eyedrops
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: T1225 1.0% and 1.5% eyedrops
Number of subjects: 91
Study: 16583149

Group type: EXPERIMENTAL
Intervention: Hertra 1 implantation
Number of subjects: 100

Group type: COMPARATOR
Intervention: PerFix Plug
Number of subjects: 100
Study: 14695501

Group type: EXPERIMENTAL
Intervention: Tetracaine 4% gel (1.0 g)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo control (1.0 g of eucerin-plus cream)
Number of subjects: 49
Study: 11056593

Group type: EXPERIMENTAL
Intervention: rhNGF, 0.1 microg/kg, subcutaneous injection 3 times per week for 48 weeks
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Placebo, subcutaneous injection 3 times per week for 48 weeks
Number of subjects: 1019
Study: 8831327

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg and Sch 1.5 mg/kg (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg and Sch 1.5 mg/kg (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg, alfentanil 40 micrograms/kg, and Sch 1.5 mg/kg (Group III)
Number of subjects: 60
Study: 1336347

Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g) and tazobactam (500 mg) every 8 h
Number of subjects: 134

Group type: COMPARATOR
Intervention: Imipenem (500 mg) and cilastatin (500 mg) every 8 h
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 134

Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 134
Study: 3912620

Group type: EXPERIMENTAL
Intervention: CMF plus tamoxifen (CMFT)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: CMFT plus BCG vaccinations
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: ER measurements in the primary tumor
Number of subjects: 312
Study: 31494097

Group type: EXPERIMENTAL
Intervention: AMG 714 (8 mg/kg, 7 intravenous doses over 10 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 10 weeks)
Number of subjects: 28
Study: 29480848

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 27542322

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) 50mg/100mg once daily for 12 weeks (n=129)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Sofosbuvir (SOF) 400mg once daily plus pegylated interferon/ribavirin (PR) for 12 weeks (n=128)
Number of subjects: 257
Study: 25171575

Group type: EXPERIMENTAL
Intervention: Insufflation by intermittent positive-pressure breathing (IPPB) combined with manually assisted coughing (MAC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) combined with manually assisted coughing (MAC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) combined with MAC
Number of subjects: 18

Group type: COMPARATOR
Intervention: Insufflation-exsufflation alone
Number of subjects: 18
Study: 23241571

Group type: EXPERIMENTAL
Intervention: Weight loss after gastric bypass surgery
Number of subjects: 100
Study: 20053140

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0